CA Patent

CA2920317A1 — Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies

Assigned to University of Washington · Expires 2015-02-19 · 11y expired

What this patent protects

Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject …

USPTO Abstract

Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.

Drugs covered by this patent

Patent Metadata

Patent number
CA2920317A1
Jurisdiction
CA
Classification
—
Expires
2015-02-19
Drug substance claim
No
Drug product claim
No
Assignee
University of Washington
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.